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External pneumatic compression (EPC) devices
are an effective method of prophylaxis against lower
extremity deep venous thrombosis (DVT), reducing
the incidence of DVT to levels comparable to those
achieved with anticoagulation.1,2 The efficacy of
these devices has been demonstrated in many patient
groups, including those undergoing general surgi-
cal,3,4 neurosurgical,5 orthopedic,6,7 and urologic
procedures.8
The primary mechanism of action of EPC devices
is a reduction in lower extremity venous stasis, mea-
sured as increased flow velocities in major axial veins
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Introduction: External pneumatic compression (EPC) devices prevent lower extremity
deep venous thrombosis by increasing venous flow and thereby reducing stasis. Early
studies suggested that they also enhance systemic fibrinolytic activity and thus prevent
thrombus formation; more recent studies have been conflicting. The hypothesis of this
study was that EPC devices enhance systemic fibrinolysis or reduce postoperative fibri-
nolytic impairment in patients undergoing abdominal surgical procedures.
Methods: Each of 48 patients (98% male; mean age, 67 years) undergoing major intra-
abdominal surgical procedures (36 bowel procedures, 12 aortic reconstructions) was
prospectively randomized to one of three treatments for deep venous thrombosis pro-
phylaxis: subcutaneous heparin injections (HEP group), use of a thigh-length sequential
EPC device (EPC group), or both (HEP + EPC group). Antecubital venous samples
were collected for measurement of systemic fibrinolytic activity on the day before
surgery, after induction of anesthesia but before prophylaxis was initiated, and on post-
operative days 1, 3, and 5. Fibrinolysis was assessed through measurement of the activ-
ities of the rate limiting fibrinolytic activator, tissue plasminogen activator, and its
inhibitor plasminogen activator inhibitor-1 with amidolytic methods.
Results: On the day before surgery, plasminogen activator inhibitor-1 activity was ele-
vated in all groups in comparison with that in age-matched and sex-matched controls
(20.3 ± 0.6 AU/mL). In the HEP group, plasminogen activator inhibitor-1 activity was
further elevated above the value for the day before surgery on postoperative day 1 (28.5
± 4.3 AU/mL; P = .04) and postoperative day 3 (25.1 ± 1.9 AU/mL; P = .07). No sig-
nificant decrease in plasminogen activator inhibitor-1 activity occurred in either group
treated with EPC devices in comparison with the HEP group at any time. There were
no changes in tissue plasminogen activator activity postoperatively in the HEP group
and no significant increases in either EPC group at any point.
Conclusions: Reduced systemic fibrinolytic activity (“fibrinolytic shutdown”) occurred in
these patients after abdominal surgery; it was manifested as increased plasminogen acti-
vator inhibitor-1 activity. EPC devices did not enhance systemic fibrinolysis or prevent
postoperative shutdown either by decreasing plasminogen activator inhibitor-1 activity
or by increasing tissue plasminogen activator activity. These data suggest that EPC
devices do not prevent deep venous thrombosis by fibrinolytic enhancement; effective
prophylaxis is achieved only when the devices are used in a manner that reduces lower
extremity venous stasis. (J Vasc Surg 2000;32:537-43.)
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of the legs.4,9-11 A second proposed mechanism of
action is enhancement of endogenous fibrinolysis,
the system by which the body lyses excess or inap-
propriately formed thrombus. Evidence supporting
this mechanism was originally provided in 1976 by
Knight and Dawson,12 who showed that application
of a pneumatic compression device to an arm result-
ed in enhanced fibrinolytic activity and reduced inci-
dence of DVT in the leg. Subsequently, Tarnay et
al,13 Caprini et al,14 Salzman et al,15 Inada et al,16
and Summaria et al17 showed EPC-mediated
improvement in fibrinolysis in both normal volun-
teers and patients undergoing surgical procedures.
At the time of these early studies, measurement
of fibrinolytic activity was crude and nonspecific,
consisting primarily of euglobulin clot lysis time
(ECLT), the time required for lysis of a fibrin clot by
the addition of a subject’s serum.18 Recently, the
enzymatic mechanism by which fibrinolysis occurs
has been elucidated, and measurement of the indi-
vidual rate-limiting proteases is now possible.
Fibrinolysis results from the activity of tissue plas-
minogen activator (tPA), which cleaves the inactive
zymogen plasminogen to its active form, plasmin.
Plasmin, in turn, cleaves fibrin clots. Inhibition of
fibrinolysis occurs predominantly through the action
of plasminogen activator inhibitor-1 (PAI-1) by for-
mation of a 1:1 stoichiometric complex with tPA.
Only free tPA and PAI-1 are biologically active.19
With the availability of new methods for quan-
tification of the specific components of fibrinolysis,
investigators have measured the effect of EPC
devices on systemic fibrinolysis in normal volun-
teers.20,21 A small but significant decrease in PAI-1
activity in normal volunteers treated with EPC
devices was noted by one group,20 but other inves-
tigators found conflicting results.21 Unpublished
data from our laboratory also failed to demonstrate
any significant enhancement of systemic fibrinolysis
with the use of EPC devices in normal volunteers.
“Fibrinolytic shutdown,” a reduction in fibri-
nolytic activity, is present for a period of 1 to 5 days
after surgical procedures, predisposing patients to
both venous thromboembolism and atherothrom-
botic events, such as myocardial infarction.22,23 The
hypothesis of the study presented here was that EPC
would improve fibrinolytic activity or prevent post-
operative shutdown in subjects undergoing major
intra-abdominal surgical procedures.
METHODS
The study group consisted of 48 patients (47
male, 1 female; mean age, 67 years) undergoing
major abdominal surgery. Each was randomized to
one of three groups for DVT prophylaxis: subcuta-
neous heparin injections (5000 units twice a day;
HEP group), use of a thigh-length sequential pneu-
matic compression device (Kendall Health Care,
Manchester, Mass; EPC group), or both (HEP +
EPC). The surgical procedures that were performed
are listed in Table I; they included 12 aortic recon-
structions (all abdominal aortic aneurysm repairs),
24 resections for malignancy, and 12 miscellaneous
laparotomies (11 bowel resections/lysis of adhe-
sions, 1 splenectomy).
Each patient underwent preoperative venous
duplex ultrasound scanning to exclude the presence
of preexisting venous disease, and a second ultra-
sound scan was performed either on postoperative
day 5 or before discharge to rule out the develop-
ment of DVT. Patients with preexisting venous dis-
ease, a history of venous thromboembolism, or a
preoperative or postoperative requirement for sys-
temic anticoagulation (with the exception of the 12
patients undergoing aortic aneurysm repair, who did
receive systemic doses of heparin intraoperatively)
were excluded from the study. Ultrasound scans
were performed from the popliteal vein to the iliac
veins; calf veins were not routinely scanned. The cri-
teria for a positive ultrasound for both acute and
JOURNAL OF VASCULAR SURGERY
538 Cahan et al September 2000
Table I. Demographics of patient groups
HEP EPC HEP + EPC
No. of subjects 17 16 15
Age* (y) 66.6 ± 2.8 66.1 ± 3.0 68.8 ± 2.7
Surgical procedures (N; % of group)
Aortic reconstructions 4 (24) 6 (37.5) 2 (13)
Abdominal cancer procedures 10 (59) 6 (37.5) 8 (53)
Colectomies 9 5 7
Esophagectomies 0 1 1
Whipple procedure 1 0 0
Miscellaneous laparotomies 3 (17) 4 (25) 5 (34)
*Mean ± SEM; P > .05 for difference among groups (by analysis of variance).
nonacute DVT have been previously described.24
DVT prophylaxis was initiated in the operating
room after induction of anesthesia and continued
until postoperative day 5 (or discharge, if this
occurred sooner). If the patient remained hospital-
ized after postoperative day 5, DVT prophylaxis was
left to the discretion of the primary surgeon, and the
patient was no longer participating in this research
study. To ensure that the EPC device remained on
the patient and was working, a study coordinator
checked the device twice a day while the patient was
in the study, between 8 and 10 AM and between 3
and 5 PM.
Fibrinolysis was assessed by measurement of the
biologic activities of tPA and PAI-1. Antecubital
venous blood samples were collected for measure-
ment of systemic fibrinolytic activity on the day
before surgery (PREOP), after induction of anesthe-
sia but before the initiation of prophylaxis (ANES),
and on postoperative day (POD) 1, POD 3, and
POD 5. All samples were collected between 7 and
11 AM to eliminate the known diurnal variations in
fibrinolysis.25 For determination of tPA activity,
blood was first collected into 130 mmol/L of sodi-
um citrate anticoagulant (9:1 volume) and immedi-
ately acidified by the addition of 0.5 mmol/L of
sodium acetate, pH 4.2 (2:1 volume), to prevent the
ongoing in vitro inactivation of tPA by complex for-
mation with PAI-1.26 Samples for measurement of
PAI-1 activity were collected into a 5-mL syringe
containing modified Files solution (1 mL of acid cit-
rate dextrose solution, 80 µL of acetylsalicylic acid
solution, and 10 µL of prostaglandin E1) to mini-
mize in vitro platelet activation (final dilution 1:5).27
Samples were maintained at 45ºC until centrifuga-
tion at 10,000g for 20 minutes. Platelet-poor plasma
was stored at –80ºC until assays were performed.
The activity levels of tPA and PAI-1 were mea-
sured through use of an amidolytic method.28 All
assays were performed in duplicate, and interassay
variability was determined to be less than 5%. tPA
activity was expressed in international units
(IU/mL), assessed against the 2nd International
Standard for tPA from the National Institute for
Biological Standards and Control.29 PAI-1 activity
was expressed in arbitrary units (AU) per milliliter,
one arbitrary unit of inhibitor being defined as the
amount that inhibits 1 IU of tPA per milliliter of
plasma.30
Values for tPA and PAI-1 activity were combined
for all subjects in each group at each time point.
Data are expressed as mean ± SEM. Changes in sys-
temic fibrinolytic activity over time were compared
with PREOP values within each group through use
of the Student t test. Changes in each of the EPC
groups were compared with those in the HEP group
at each time point, also through use of the Student
t test. Differences in the frequencies of procedures
among the groups were determined by means of the
Fisher exact test. A P value of less than .05 was
required for statistical significance. The protocol was
approved by the Institutional Review Board of the
University of Maryland, and all subjects gave
informed consent before participating.
RESULTS
Subjects and procedures. There were no signif-
icant differences among the three groups with
respect to age or sex (Table I). The frequency of aor-
tic reconstructions was higher in the EPC group
than in the HEP and HEP + EPC groups (37.5% vs
24% and 13%, respectively; P < .05, Fisher exact
test). The frequency of procedures performed for
malignancy was similar among the groups (P > .05,
Fisher exact test; Table I). The prevalence of athero-
sclerosis in the coronary, cerebral, and peripheral cir-
culations was similar in the three groups (75% vs
62% vs 67%; P > .05, Fisher exact test). No patient
enrolled in the study had venous disease identified
by means of preoperative duplex ultrasound scan-
ning. Forty-one (85%) of the 48 patients underwent
postoperative duplex ultrasound scanning; no proxi-
mal DVTs were identified. No patient developed
symptoms of venous thromboembolism during the
study period.
tPA activity. Samples from subjects in all groups
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Table II. tPA activity (IU/mL) over time in each group
Group PREOP* ANES* POD 1 POD 3 POD 5
HEP 1.4 ± 0.1 1.5 ± 0.1 (.75†) 1.4 ± 0.3 (.82†) 1.5 ± 0.3 (.51†) 1.6 ± 0.3 (.43†)
EPC 1.5 ± 0.2 (.69†) (.98‡) 1.3 ± 0.2 (.37†) (.16‡) 1.5 ± 0.3 (.98†) (.60‡)
HEP + EPC 2.0 ± 0.4 (.07†) (.29‡) 1.6 ± 0.4 (.74†) (.47‡) 1.8 ± 0.5 (.46†) (.69‡)
*Samples for subjects in all groups are pooled because no prophylaxis was initiated.
†P value vs PREOP.
‡P value vs HEP at same time point.
were pooled at the PREOP and ANES time points,
inasmuch as prophylaxis had not been initiated.
PREOP tPA activity was 1.4 ± 0.1 IU/mL. No sig-
nificant change occurred after induction of anesthe-
sia (ANES; P = .75), and no changes occurred in the
HEP group in comparison with PREOP at any sub-
sequent time point (P > .05; Table II). tPA activity
in each of the EPC groups (EPC and HEP + EPC)
was compared with that in the HEP group on PODs
1, 3, and 5; again, no significant increases in activity
could be identified (P > .05; Table II).
PAI-1 activity. PREOP PAI-1 activity was 20.3
± 0.6 AU/mL (Table III). PAI-1 activity increased
after induction of anesthesia (ANES) and again on
POD 1 in the HEP group, in whom it reached a
maximum level of 28.5 ± 4.3 AU/mL (P = .04 vs
PREOP). It returned to baseline by POD 5. PAI-1
activity increased in the EPC group after surgery,
but this did not reach statistical significance. In the
HEP + EPC group, PAI-1 activity was significantly
elevated on POD 1 (30.8 ± 2.8 AU/mL; P = .01),
indicating further impairment of systemic fibrinoly-
sis, and returned to baseline by POD 3. There were
no significant decreases in PAI-1 activity in either of
the EPC groups in comparison with the HEP group
at any time point (Table III).
Influence of malignancy on tPA and PAI-1
activities. Twenty-four (50%) of the 48 patients in
this study underwent laparotomy for intra-abdomi-
nal malignancy. Because malignancy produces a
hypercoagulable state with impairment of fibrinoly-
sis, the data were reanalyzed after the patients were
classified according to the presence or absence of
cancer. For this analysis, the EPC and HEP + EPC
groups were combined to increase the number of
patients per group.
In the patients without cancer, PREOP tPA
activity was 1.7 ± 0.1 IU/mL (Tables IV and V).
This was significantly lower in the group with cancer
(1.1 ± 0.3 IU/mL; P = .004). PREOP PAI-1 activ-
ity in cancer-free patients was 20.6 ± 2.0 AU/mL.
There was a trend toward increased PREOP PAI-1
activity in the patients with cancer, but this did not
achieve statistical significance (24.3 ± 1.4 AU/mL;
P = .27). No significant improvement in systemic
fibrinolysis (increased tPA activity, decreased PAI-1
activity) occurred in either the HEP group or the
EPC group in patients with cancer or patients with-
out cancer at any time point after PREOP.
Furthermore, there was no significant improvement
in either fibrinolytic variable in the EPC group com-
pared with the HEP group in patients with cancer or
patients without cancer at any time point.
DISCUSSION
Enhancement of fibrinolytic activity by EPC
devices was first proposed by Knight and Dawson12
in 1976, after they observed increased fibrinolytic
activity and a reduced incidence of DVT in the leg
after placement of an EPC device on an arm.
Subsequent studies primarily evaluated the effect of
EPC on ECLT, a nonspecific measure of global fibri-
nolysis, in patients undergoing surgical procedures.
Thus, Allenby et al31 found reduced fibrinolysis
(measured as increased ECLT) postoperatively
(“postoperative fibrinolytic shutdown”) in patients
undergoing abdominal surgical procedures. EPC
devices produced a small but significant (10%)
decrease in postoperative ECLT (enhanced fibrinoly-
sis) in patients undergoing surgery for nonmalignant
disease, although not in subjects with malignancy.
Salzman et al15 found that EPC protected against
postoperative fibrinolytic shutdown in patients
undergoing neurosurgical procedures, and Inada et
al16 found similar results in patients undergoing sur-
gical procedures for malignancy. Caprini et al14
demonstrated reduced postoperative fibrinolytic
shutdown in patients undergoing orthopedic or neu-
rosurgical procedures but not in patients undergoing
abdominal surgery.
A single early study13 addressed the effects of
EPC on fibrinolysis in normal volunteer subjects.
EPC applied to one arm did not produce a statisti-
cally significant increase in fibrinolytic activity mea-
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Table III. PAI-1 activity (AU/mL) over time in each group
Group PREOP* ANES* POD 1 POD 3 POD 5
HEP 20.3 ± 0.6 23.0 ± 1.8 (.29†) 28.5 ± 4.3 (.04†) 25.1 ± 1.9 (.07†) 23.7 ± 3.1 (.28†)
EPC 20.1 ± 2.8 (.95†) (.13‡) 24.4 ± 1.8 (.11†) (.81‡) 24.2 ± 1.3 (.10†) (.88‡)
HEP + EPC 30.8 ± 2.8 (.01†) (.76‡) 23.2 ± 1.5 (.44†) (0.61‡)
*Samples for subjects in all groups are pooled because no prophylaxis was initiated.
†P value vs PREOP.
‡P value vs HEP at same time point.
sured in the contralateral arm, but it did produce a
small (6%) increase in systemic activity when applied
to both legs.
Although most clinicians concluded that improved
fibrinolysis contributed to the effectiveness of EPC
devices and used them in this fashion, the findings of
these early studies do not support this conclusively.
Neither systemic fibrinolytic enhancement in normal
volunteer subjects nor prevention of postoperative fibri-
nolytic shutdown in patients undergoing surgery was
uniformly observed. Moreover, many of the variables
that affect fibrinolysis (eg, age32 and time of day25)
were unknown at the time, and study designs did not
incorporate control of these variables. Some studies
were nonrandomized and did not contain appropriate
control groups. Finally, studies were hampered by the
use of ECLT assays to quantify fibrinolysis.
Two recent studies address the effects of EPC
devices on the specific enzymatic components of fibri-
nolysis in normal volunteer subjects. Comerota et al20
studied the effects of five EPC devices on systemic tPA
and PAI-1 activities measured from antecubital venous
samples. These investigators found small but signifi-
cant decreases in systemic PAI-1 activity (9.6 to 7.4
mU/mL; P = .003) after 3 hours of pumping with
each EPC device. The study used modern methods for
quantification of fibrinolysis and controlled for many
variables now known to affect it.
Jacob et al21 also measured the effect of an EPC
device on systemic fibrinolysis in normal volunteer
subjects, although sampling was performed from the
inferior vena cava rather than from an antecubital
vein, which is what Comerota et al20 had used.
These investigators found that placement of an
indwelling venous catheter was associated with
increased PAI-1 antigen levels that continued for 4
hours after placement. Pumping with a sequential
EPC device resulted in decreased PAI-1 antigen dur-
ing an initial pumping period, but no changes were
noted during a second period of pumping. 
In the study reported here, postoperative “fibri-
nolytic shutdown,” manifested as increased PAI-1
activity, occurred in 2 of the 3 groups. This is con-
sistent with the findings of previous studies, in which
PAI-1 activity was found to be elevated after surgery
in multitrauma22 and vascular23 patients. However,
neither group treated with EPC devices experienced
decreased PAI-1 at any point in comparison with the
HEP group. No significant changes in tPA activity
occurred relative to PREOP in any group, and there
were no significant differences among groups. These
results suggest that the EPC device tested here does
not enhance systemic fibrinolysis or prevent postop-
erative shutdown in patients undergoing abdominal
surgery.
Differences between these results and those of
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Table IV. tPA activity (IU/mL) in cancer-free patients vs patients with cancer
Patients PREOP POD 1 POD 3 POD 5
Cancer-free 1.7 ± 0.1*
HEP† 1.5 ± 0.9 1.4 ± 0.7 2.3 ± 1.6
EPC†‡ 2.0 ± 0.9 1.6 ± 0.3 2.1 ± 0.3
With cancer 1.1 ± 0.1*
HEP† 1.4 ± 0.4 1.6 ± 0.4 1.6 ± 0.2
EPC†‡ 1.4 ± 0.3 1.2 ± 0.2 2.0 ± 0.9
*All samples are pooled because no prophylaxis was initiated. For cancer-free patients vs patients with cancer, P = .004.
†For all POD samples for each group vs PREOP, P > .05.
‡For EPC vs HEP at each time point, P > .05.
Table V. PAI-1 activity (AU/mL) in cancer-free patients vs patients with cancer
Patients PREOP POD 1 POD 3 POD 5
Cancer-free 20.6 ± 2.0*
HEP† 29.3 ± 3.5 24.4 ± 2.8 29.0 ± 3.1
EPC†‡ 23.9 ± 1.4 24.6 ± 1.6 25.9 ± 1.4
With cancer 24.3 ± 1.4*
HEP† 21.2 ± 2.5 27.2 ± 4.5 22.9 ± 2.7
EPC†‡ 29.1 ± 2.7 26.0 ± 2.4 26.7 ± 1.9
*All samples are pooled because no prophylaxis was initiated. For cancer-free patients vs patients with cancer, P = .27.
†For all POD samples for each group vs PREOP, P > .05.
‡For EPC vs HEP at each time point, P > .05.
Comerota et al20 and Jacob et al21 may be related to
differences in study design. The mean age of the
patients in this study was 67 years; Comerota et al
and Jacob et al used volunteer subjects between the
ages of 20 and 40 years. Fibrinolytic activity is
known to decline with age.32 One half of the
patients in this study underwent surgery for intra-
abdominal malignancy; cancer reduces fibrinolysis
and produces a hypercoagulable state.33,34 In fact,
consistent with findings in previous studies,34
patients with cancer had significantly lower baseline
tPA activity values than patients without cancer, and
they also had a trend toward higher PAI-1 activity.
In this study, sampling was performed over a period
of days rather than hours (as in the studies of both
Comerota et al and Jacob et al). Although an early
period (a number of hours) of increased systemic
fibrinolysis might have occurred, it must have been
transient if it did, and it must have been “overrid-
den” by the fibrinolytic shutdown present by POD
1. Finally, Jacob et al21 used measurement of antigen
levels to quantify fibrinolysis, whereas both our
study and that of Comerota et al20 used activity lev-
els. Antigen assays measure both free and bound
(inactive) tPA and PAI-1 and thus do not accurately
represent the free, biologically active portions of tPA
and PAI-1.28 PAI-1 antigen measurements, in par-
ticular, are susceptible to inaccuracy because instru-
mentation of veins results in secretion of large
amounts of inactive PAI-1 antigen from platelets.27
This may explain the observation by Jacob et al21 of
increased PAI-1 antigen levels for the first 4 hours
after catheter placement.21
The preoperative PAI-1 activity value (20.3 ± 0.6
AU/mL) in this study was higher than values previ-
ously reported for age-matched and sex-matched
normal subjects (12-16 AU/mL).35 The presence of
malignancy in a large portion of the study group
does not explain this elevation, because there was no
statistically significant difference in PAI-1 activity
between those subjects with cancer and those sub-
jects without it. The presence of other comorbidities
known to increase PAI-1 in these patients, including
atherosclerosis36 and diabetes mellitus,32 may pro-
vide an explanation for the observed increase.
This study did not address the effects of EPC
devices on urokinase-type plasminogen activator,
and possible systemic fibrinolytic enhancement
through this mechanism remains unknown. It also
remains to be determined whether EPC devices will
produce regional increases in fibrinolysis in the
lower extremity, either by increased endothelial
secretion of fibrinolytic factors or by the trapping of
these factors in the leg. However, at this time, both
improvement in systemic fibrinolysis and prevention
of postoperative fibrinolytic shutdown in patients
undergoing surgical procedures must be considered
unproven. Until more data are available, effective
and safe prophylaxis with EPC can be assured only
when the devices are used in a manner that reduces
lower extremity venous stasis.
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